MF
AEGR

Magnetar Financial’s Aegerion Pharmaceuticals AEGR Stock Holding History

Magnetar Financial’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-7,063
Closed -$447K – 540
2013
Q2 		$447K Buy
+7,063
New +$375K 0.01% 311

Other funds holding AEGR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Magnetar Financial's AEGR Position: Q3 2013 in Review

Magnetar Financial sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2013, closing a stake of 7,063 shares — an estimated $447K sold.

Magnetar Financial first reported a position in AEGR in Q2 2013 and held it in 1 quarter. The position peaked at $447K in Q2 2013. 154 funds tracked by Wall St. Rank hold AEGR as of Q3 2013.

  • Magnetar Financial reported no remaining Aegerion Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Magnetar Financial sold 7,063 Aegerion Pharmaceuticals shares in Q3 2013, an estimated $447K.
  • Magnetar Financial first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Magnetar Financial's Aegerion Pharmaceuticals position peaked at $447K in Q2 2013.
  • 154 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2013.

Based on Magnetar Financial's 13F filing for Q3 2013, filed 14 Nov 2013.